Welcome to our dedicated page for Stryker Corporation news (Ticker: SYK), a resource for investors and traders seeking the latest updates and insights on Stryker Corporation stock.
Stryker Corporation, based in Kalamazoo, Michigan, is an American multinational renowned for its groundbreaking medical technologies. The company designs, manufactures, and markets a wide array of medical equipment and devices that play critical roles in healthcare settings around the globe.
Stryker's comprehensive product portfolio includes hip and knee replacements, endoscopy systems, operating room equipment, embolic coils, hospital beds, gurneys, and spinal devices. The company is a dominant force in the medical sector, holding a top-three position in reconstructive orthopedic implants and leading in operating room equipment.
In the most recent financial updates, Stryker reported impressive operating results for the fourth quarter and the full year of 2023. With organic sales growth exceeding 11% and surpassing $20 billion in sales, the company has shown robust performance. Kevin Lobo, Chair and CEO, attributes this success to the dedicated teams driving high growth and strong adjusted earnings.
Stryker's influence extends globally, impacting over 150 million patients annually through its work in MedSurg, Neurotechnology, Orthopaedics, and Spine. Just over a quarter of its total revenue is generated from markets outside the United States, highlighting its international presence and reach.
The company continues to innovate and expand its horizons. For instance, Stryker will disclose its financial results for the first quarter of fiscal year 2024 on April 30, 2024. This forthcoming report is anticipated to provide further insights into the company’s financial health and ongoing projects.
For those interested in staying updated, Stryker's press releases and financial disclosures are readily available on their website. The corporation maintains a strong commitment to improving healthcare outcomes and enhancing patient care through its innovative products and services.
Stryker (NYSE: SYK) has entered into a definitive agreement to acquire Vocera Communications (NYSE: VCRA) for $79.25 per share, totaling approximately $2.97 billion in equity value. The deal enhances Stryker's Medical division by integrating Vocera's innovative digital care coordination platform, which aims to alleviate caregiver burdens and improve patient outcomes. Both companies' boards have unanimously approved the transaction, expected to close in Q1 2022, with a neutral impact on Stryker's 2022 net earnings per share.
Stryker (NYSE:SYK) will host a conference call on January 27, 2022, at 4:30 p.m. ET to discuss its operating results for Q4 2021, with final results released at 4:05 p.m. the same day. Interested parties can register for the call through this link. The call will also be available via a webcast on Stryker's Investor Relations page. A replay will be accessible afterward at provided numbers with a passcode.
Stryker is a global leader in medical technology, focusing on improving healthcare outcomes through innovative products.
Stryker (NYSE:SYK) announced a quarterly dividend increase to $0.695 per share, payable on January 31, 2022, to shareholders of record as of December 31, 2021. This marks a 10.3% increase compared to the previous year and quarter. CEO Kevin Lobo emphasized the company's strong sales growth and solid financial results, aligning with their capital allocation strategy. Stryker is recognized as a leading medical technology firm, focused on improving healthcare through innovative products across Orthopaedics, Medical and Surgical, and Neurotechnology and Spine.
Moss & Gilmore LLP announced a settlement with the U.S. Department of Justice regarding a False Claims Act lawsuit. Defendants Jeffrey M. Gallups, M.D., and Milton Hall Surgical Associates will pay $3,068,434 to resolve allegations of ordering unnecessary medical tests and surgeries for kickbacks. Entellus Medical, acquired by Stryker Corporation (NYSE:SYK), will also pay $1,200,000 for its involvement. Dr. Gallups previously pleaded guilty to healthcare fraud, with sentencing set for February 11, 2022. Failure to pay may result in a $5,388,863 judgment against them.
Stryker reported third-quarter results for 2021, with net sales of $4.2 billion, representing an 11.3% increase from 2020 and a 16.0% increase from 2019. Although organic net sales rose 4.5% year-over-year, reported operating income margin fell by 260 bps to 25.4%. Reported EPS decreased by 30.1% to $1.14, while adjusted EPS rose 2.8% to $2.20. Key segments showed varied growth, with Orthopaedics increasing by 16.1% but experiencing a decline in organic sales. The company adjusted its 2021 outlook, forecasting organic sales growth of 7% to 8% from 2019.
Stryker (NYSE:SYK) will host an Analyst Meeting on November 18, 2021, at 2:30 p.m. ET, in Mahwah, New Jersey. A webcast of the event will be available on Stryker's website, where it will be archived for later viewing. To join via phone, call (844) 200-6205 (domestic) or (929) 526-1599 (international) with access code 695616. A recorded version will be accessible from 8:30 p.m. ET on November 18 until 11:59 p.m. ET on November 25, 2021. For further inquiries, contact their Investor Relations team.
Stryker (NYSE:SYK) will host a conference call on October 28, 2021, at 4:30 p.m. ET to discuss operating results for the quarter ending September 30, 2021. Preliminary results will be released at 4:05 p.m. that day. Participants can join by calling (833) 979-2711 (domestic) or (236) 714-2206 (international) with passcode 7351349. The call will be available via webcast on the company's website and archived after for later access until November 4, 2021.
Stryker is a leading medical technology company focused on enhancing healthcare.
THINK Surgical, Inc. has appointed Stuart F. Simpson as its new president and chief executive officer. With over 24 years at Stryker Corporation (NYSE: SYK), Simpson brings extensive experience in the orthopedic device sector, having previously led the Joint Replacement Division. He is confident about THINK's growth potential, particularly due to its innovative technology and open implant platform, which are believed to drive customer value and operational improvements. The company's robotic system has been used in numerous successful joint replacement surgeries worldwide.
Stryker (NYSE:SYK) will participate in Morgan Stanley’s 19th Annual Global Healthcare Conference on September 13, 2021. CEO Kevin Lobo will present virtually at 10:15 a.m. ET. The presentation will be available for live streaming and later replay on the Stryker website. Known for its innovative solutions in Orthopaedics, Medical and Surgical, and Neurotechnology, Stryker aims to enhance healthcare outcomes globally. For more information, visit www.stryker.com.
Stryker (NYSE:SYK) announced on August 18, 2021, that Timothy J. Scannell will retire as President and COO on March 31, 2023. He will serve as Advisor to the CEO from October 1, 2021, until retirement, ensuring a smooth transition of duties to Group Presidents J. Andrew Pierce and Spencer S. Stiles. Scannell has had a notable 31-year career at Stryker, contributing to its growth and success. The company remains focused on innovative medical technologies aimed at improving healthcare outcomes.
FAQ
What is the current stock price of Stryker Corporation (SYK)?
What is the market cap of Stryker Corporation (SYK)?
What does Stryker Corporation specialize in?
Where is Stryker Corporation headquartered?
How did Stryker perform financially in 2023?
What is the scope of Stryker's global impact?
What are some of the products offered by Stryker?
When will Stryker report its financial results for Q1 2024?
How can I access Stryker's financial reports?
Who should I contact for investor inquiries at Stryker?
What areas does Stryker focus its innovations on?
How can I stay updated with Stryker's latest developments?
